Table 2.
Patient | Diagnosis | INR | Albumin, g/dl | Sodium, mmol/l | Total bilirubin, mg/dl | Direct bilirubin, mg/dl | Platelets × 103/µl |
---|---|---|---|---|---|---|---|
1 | Biliary atresia | 1.2 | 1.8a | 137 | 1.0 | 0.4 | 42 |
2 | Biliary atresia | 1.2 | 4.3 | 136 | 0.4 | 0 | 93 |
3 | Biliary atresia | 1.5 | 2.1a | 135 | 0.6 | 0.2 | 97 |
4 | Biliary atresia | 1.3 | 2.5b | 141 | 9.8b | N/A | 81 |
5 | Congenital hepatic fibrosis | 1.2 | 4.2 | 138 | 1.7 | 0.4 | 110 |
6 | Congenital hepatic fibrosis | 1.2 | 3.8 | 138 | 0.2 | 0.4 | 81 |
7 | Cryptogenic cirrhosis | 1.3 | 3.7 | 139 | 2.9 | 1.7 | 59 |
8 | Cryptogenic cirrhosis | 1.6 | 2.9a | 141 | 1.5 | 0.7 | 37 |
9 | Autoimmune hepatitis | 1.3 | 4.3 | 130 | 1.4 | 0.3 | 49 |
10 | Wilson's disease | 1.5 | 3 | 137 | 2.5 | 0.7 | 80 |
11 | Cystic fibrosis | 1.3 | 3.3 | 140 | 0.6 | 0.2 | 102 |
12 | Lymphoma | 1.3 | 2.1c | 137 | 5.4c | 5.2 | 50 |
Low albumin was noted acutely in association with gastrointestinal bleeding and was >3 mg/dl preceding the bleed and during follow-up after the surgical shunt procedure
Patient 4 had an emergency mesocaval shunt for a gastrointestinal bleed that could not be controlled medically
Patient 12 had a portosystemic shunt to facilitate chemotherapy for lymphoma
INR, international normalized ratio; N/A, not available